PhaseV Closes 2025 with Record Growth, Supporting Biopharma's Shift from AI Pilots to Full-Scale Execution

PhaseV, an AI/ML platform for clinical development, reported significant growth in 2025, with revenues growing almost five-fold. Their AI-driven platform has shown to reduce trial costs by 50% and decrease enrollment size and trial duration by 40%.